SCHD’s dividend quality filter now concentrates over 40 percent of your money in just ten stocks

Most investors buy Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) because the fund's reputation tells them they are buying diversification. SCHD holds roughly 103 stocks, screens hard on dividend quality, and charges 0.06%.

The retiree who built an income sleeve around SCHD usually has not read the holdings list. Read the list and the diversification story bends quickly: the top ten positions account for about 41.7% of the fund, a level well above the 30% top-ten weight typical of large-cap dividend peers.

What SCHD does

The fund tracks the Dow Jones U.S. Dividend 100 Index, which screens U.S. companies on a ten-year dividend history, cash flow to total debt, return on equity, dividend yield, and five-year dividend growth. The portfolio reconstitutes each March and rebalances quarterly, producing a quality-tilted dividend basket built around mature businesses paying ordinary qualified dividends out of operating cash flow.

The screen does its job at the security level. Following the June 2026 rebalance, healthcare names dominate the top of the book: UnitedHealth (NYSE:UNH) has taken the number-one spot, with healthcare leaders occupying four of the top positions. Technology names Texas Instruments (NASDAQ:TXN) and Qualcomm (NASDAQ:QCOM) have faded toward the bottom of the top tier. Each name passes the quality filter. The aggregation is what the brochure does not advertise.

Does it deliver?

So far in 2026, yes. SCHD is up roughly 22% on a total-return basis, comfortably outpacing the broader market, as investors have rotated from richly valued growth names into defensive cash flows. That said, the ride has not been smooth: oil spiked to over $117 per barrel for Brent in March after military action disrupted Middle East supply, then retreated sharply after the U.S. and Iran signed a memorandum of understanding in June to reopen the Strait of Hormuz. Energy names gave back much of their gains. The volatility illustrates exactly the kind of single-sector shock the fund's dividend-history filter cannot anticipate.

Extend the window and the picture shifts. Over five years, SCHD has delivered a total return of roughly 52%, a respectable figure for a yield-oriented fund but still well behind the S&P 500's growth-led run over the same span.

The tradeoffs the fact sheet underplays

Three concentrations are worth pricing in before you treat SCHD as a diversifier.

1. The pharma cluster. Many of SCHD's pharma holdings are navigating patent cliffs. Biosimilar competition pushed AbbVie's (NYSE:ABBV) Humira sales to $688 million in the first quarter of 2026, a 38.6% decline year over year. The silver lining is that AbbVie's total Q1 revenue still grew 12.4% to roughly $15 billion, carried by Skyrizi and Rinvoq. Even so, the screen rewarded AbbVie's dividend history. It cannot see which formulas are expiring next.
2. Energy holdings move with the same barrel of oil. The 2026 oil story crystallizes the risk: Brent swung from roughly $61 per barrel in January to a peak near $117 in March, then fell back as the Strait of Hormuz threat eased. A sharp simultaneous drawdown across the fund's energy names would carve directly into a meaningful slice of the portfolio before the rest of the book has a vote. With Hormuz now reopened and additional supply returning, the EIA projects Brent averaging around $74 per barrel in the third quarter of 2026, which is a headwind for energy dividends.
3. The distribution trajectory. SCHD's quarterly payout has historically grown steadily, rising from $0.12 per share in 2011 to $0.26 in early 2026. But Q2 2026 came in at $0.253, slightly below the comparable 2025 quarter. Two consecutive quarters of year-over-year declines in the distribution deserve scrutiny for investors who rely on SCHD specifically for income growth.

How SCHD compares to the simpler alternative

The Vanguard High Dividend Yield ETF (NYSEARCA:VYM) charges 0.04%, holds around 605 stocks as of mid-2026, and runs a far flatter weighting. Its top ten positions account for roughly 26% of assets, compared to over 40% for SCHD. You give up SCHD's quality screen, and over the past decade SCHD has edged VYM with annualized returns of about 12.5% versus 11.5%. In exchange, VYM's broader roster reduces the impact of any single sector's bad year.

For the retiree who chose SCHD because they wanted diversification, VYM is the version that actually delivers it structurally. The tradeoff is a lower yield: SCHD's current yield runs roughly 3%, while VYM sits closer to 2.4%. Over ten years SCHD has outperformed, but the gap narrows over shorter windows, and VYM's much wider spread of names means single-sector shocks hit the overall portfolio with less force.

So, should you buy SCHD?

SCHD remains one of the cleanest dividend products on the shelf: low cost, qualified-dividend-friendly, and built around businesses that have maintained payouts for a decade. It belongs in the income sleeve of an investor who understands they are also accepting ten meaningful single-stock bets beneath the surface.

If pharma patent cliffs and energy price cycles feel too concentrated for your risk tolerance, consider pairing SCHD with a flatter-weighted dividend ETF rather than leaning on it as a standalone diversifier. The two approaches are not mutually exclusive, and splitting the position can reduce sector-specific risk without abandoning SCHD's quality screen.

Editor's note: This article has been updated to reflect SCHD's current holdings count of approximately 103 stocks, the fund's post-June-2026-rebalance shift toward healthcare dominance in its top positions, revised figures on AbbVie's Q1 2026 Humira sales and total revenue, the 2026 oil price spike and subsequent retreat following the U.S.-Iran memorandum of understanding, the slight year-over-year decline in SCHD's Q2 2026 distribution, and VYM's current holdings count of approximately 605 stocks.

Contact [email protected] for any questions or corrections.